Physician profile
Lynn Sharp
NPI 1194397067
$932.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $464 · 2023: $421 · 2024: $46.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $149.73 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $124.26 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $122.92 | 2023 | Rexulti |
| Insmed, INC. | $110.20 | 2022 | |
| Jazz Pharmaceuticals INC. | $110.17 | 2022-2023 | |
| Inspire Medical Systems, INC. | $86.71 | 2023 | Inspire |
| Actelion Pharmaceuticals US, INC. | $48.22 | 2022-2023 | Uptravi |
| Mylan Specialty L.P. | $43.12 | 2022-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $33.68 | 2022 | |
| Genzyme Corporation | $24.09 | 2023 | |
| Medtronic, INC. | $24.01 | 2024 | Intellis Adaptivestim |
| Merz Pharmaceuticals, LLC | $22.85 | 2024 | Xeomin |
| Ipsen Biopharmaceuticals, INC | $17.58 | 2023 | Dysport |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2023 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.